Cleveland Biolabs holds a
performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.7166, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Cleveland's beta means in this case. As returns on the market increase, returns on owning Cleveland Biolabs are expected to decrease at a much lower rate. During the bear market, Cleveland Biolabs is likely to outperform the market. Although it is vital to follow
Cleveland Biolabs historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy in foreseeing
future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and
technical indicators. To evaluate if Cleveland Biolabs expected return of 1.17 will be sustainable into the future, we have found twenty-one different
technical indicators, which can help you to check if the expected returns are sustainable. Use Cleveland Biolabs
jensen alpha, and the
relationship between the
coefficient of variation and
potential upside to analyze future returns on Cleveland Biolabs.
How important is Cleveland BioLabs's Liquidity
Cleveland BioLabs
financial leverage refers to using borrowed capital as a funding source to finance Cleveland BioLabs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cleveland BioLabs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Cleveland BioLabs' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Cleveland BioLabs' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Cleveland BioLabs's total debt and its cash.
An Additional Perspective On Cleveland BioLabs
The current price rise of Cleveland Biolabs could raise concerns from stockholders as the firm it trading at a share price of
6.16 on very low momentum in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
May. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.43. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cleveland Biolabs partners.
Returns Breakdown
| Return on Investment | (70.89) |
| Return on Assets | (0.9) |
| Return on Equity | 0.93 |
| Return Capital | 34.1 |
| Return on Sales | (9.36) |
Another 3 percent rise for Cleveland Biolabs
Standard deviation is down to 7.36. It may hint to a possible volatility drop.
As of the 3rd of April, Cleveland Biolabs shows the
risk adjusted performance of 0.1264, and Mean Deviation of 5.34. Cleveland Biolabs
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen
technical drivers for Cleveland Biolabs, which can be compared to its rivals. Please confirm
Cleveland Biolabs jensen alpha, and the
relationship between the
coefficient of variation and
potential upside to decide if Cleveland Biolabs is priced correctly, providing market reflects its regular price of 6.16 per share. Given that Cleveland Biolabs has
jensen alpha of 1.13, we suggest you to validate Cleveland Biolabs's prevailing market performance to make sure the company can sustain itself at a future point.
Our Final Takeaway
While some other firms under the biotechnology industry are still a bit expensive, Cleveland Biolabs may offer a potential longer-term growth to stockholders. To sum up, as of the 3rd of April 2021, we believe Cleveland Biolabs is currently
overvalued. It moves indifferently to market moves and projects
high odds of financial distress in the next two years. Our overall 30 days buy-or-sell advice on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Cleveland BioLabs. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com